ONWARD® Medical anno
ONWARD® Medical annonce ses résultats financiers et opérationnels pour l’exercice 2023 et partage les faits qui ont marqué l’exercice 2024 à ce jour
26 avr. 2024 09h17 HE | ONWARD Medical NV
Dépôt auprès de la FDA d’une demande de classification du dispositif ARC-EX® System basée sur les risques (demande « De Novo ») Levée de fonds de 20 millions d’euros Annonce des résultats...
ONWARD_Logotype®_Red.png
ONWARD® Medical Reports Full Year 2023 Financial and Operating Results and Shares 2024 Highlights Year-to-Date
25 avr. 2024 01h30 HE | ONWARD Medical NV
ONWARD® Medical Reports Full Year 2023 Financial and Operating Results and Shares 2024 Highlights Year-to-Date
ONWARD_Logotype®_Red.png
ONWARD® Medical Announces Publication of Full Year 2023 Financial Results and Business Update Webcast
11 avr. 2024 01h30 HE | ONWARD Medical NV
ONWARD® Medical Announces Publication of Full Year 2023 Financial Results and Business Update Webcast
ONWARD_Logotype®_Red.png
Stifel Initiates Research Coverage of ONWARD® Medical with a Buy Rating and Target Price of EUR 12.00
09 avr. 2024 01h00 HE | ONWARD Medical NV
Stifel Initiates Research Coverage of ONWARD® Medical with a Buy Rating and Target Price of EUR 12.00
ONWARD_Logotype®_Red.png
ONWARD® Medical Submits De Novo Application to FDA for its ARC-EX® System
02 avr. 2024 01h30 HE | ONWARD Medical NV
ONWARD Medical has submitted its De Novo application to the US Food and Drug Administration (FDA) to allow marketing of its breakthrough ARC-EX System.
ONWARD_Logotype®_Red.png
ONWARD® Medical Publishes Closing of Accelerated Bookbuild Offering and Public Offering in France
25 mars 2024 12h40 HE | ONWARD Medical NV
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL....
ONWARD_Logotype®_Red.png
ONWARD® Medical Publishes Prospectus for Listing of New Shares
21 mars 2024 13h26 HE | ONWARD Medical NV
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL....
ONWARD_Logotype®_Red.png
ONWARD® Medical Lève avec Succès 20 millions d'euros dans le cadre d'une Augmentation de Capital par le biais d'une Procédure de Construction Accélérée d'un Livre d'Ordres et d'une Offre au Public en France
20 mars 2024 22h03 HE | ONWARD Medical NV
NE PAS DISTRIBUER OU DIFFUSER, DIRECTEMENT OU INDIRECTEMENT, AUX ÉTATS-UNIS, AU CANADA, EN AUSTRALIE OU AU JAPON OU DANS TOUTE AUTRE JURIDICTION DANS LAQUELLE LA DISTRIBUTION OU LA DIFFUSION SERAIT...
ONWARD_Logotype®_Red.png
ONWARD® Medical Successfully Raises €20 Million in a Capital Increase by Way of an Accelerated Bookbuild Offering and by Way of a Public Offering in France
20 mars 2024 22h03 HE | ONWARD Medical NV
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL....
ONWARD_Logotype®_Red.png
ONWARD® Medical Launches Capital Increase by Way of an Accelerated Bookbuild Offering and of a Public Offering in France for an Indicative Amount of EUR 15 Million, with an Up to EUR 5 Million Upsize Option
20 mars 2024 13h29 HE | ONWARD Medical NV
EINDHOVEN, the Netherlands, March 20, 2024 (GLOBE NEWSWIRE) -- NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER...